Schedule

Thursday, Nov. 2, 2023 | 9 a.m.–5:30 p.m. PDT

	Session I: Myeloid Cells in Cancer: Recent Advances
Time:	9–10:45 a.m. PDT
Location:	Upper Level – Ballroom 6CD San Diego Convention Center
Moderator:	Judith A. Varner, PhD – *University of California, San Diego*
9 a.m. PDT	**Introduction: Myeloid Cells in Immune Oncology** Judith A. Varner, PhD – *University of California, San Diego*
9:05 a.m. PDT	**Tumor-associated Macrophage Heterogeneity** Florent Ginhoux, PhD – *Gustave Roussy*
9:30 a.m. PDT	**Targeting the PDAC Tumor Microenvironment to Improve Anti-tumor Immunity** David G. DeNardo, PhD – *Washington University, St. Louis*
9:55 a.m. PDT	**Pre-metastatic Niche and Myeloid Cells** Rosandra N. Kaplan, MD – *National Institutes of Health/National Cancer Institute*
10:20 a.m. PDT	**Unleashing the Antitumor Potential of Neutrophil in the Context of Immune Based Intervention** Taha Merghoub, PhD – *Weill Cornell Medicine*
10:45 a.m. PDT	**Break**
	Session II: Myeloid Cell Signaling
Time:	10:55 a.m.–12:15 p.m. PDT
Location:	Upper Level – Ballroom 6CD San Diego Convention Center
Moderator:	Dmitry I. Gabrilovich, MD, PhD – *AstraZeneca*
10:55 a.m. PDT	**Introduction/Overview** Dmitry I. Gabrilovich, MD, PhD – *AstraZeneca*
11 a.m. PDT	**How do anti-TREM2 and anti-PD1 Treatments Work Together Synergistically?** Marco Colonna, MD – *Washington University School of Medicine*
11:25 a.m. PDT	**PI3 Kinase Gamma and Upstream Regulators of Immune Suppression** Judith A. Varner, PhD – *University of California, San Diego*
11:50 a.m. PDT	**Arginase 1 in Neutrophil Extracellular Traps constrains Antitumor T Cell Immunity** Vincenzo Bronte, MD – *Veneto Institute of Oncology*
12:15 p.m. PDT	**Lunch**

Schedule

	Session III: Regulation of Myeloid Cell Metabolism in Cancer
Time:	1:40–3:25 p.m. PDT
Location:	Upper Level – Ballroom 6CD San Diego Convention Center
Moderator:	Vincenzo Bronte, MD – *Veneto Institute of Oncology*
1:40 p.m. PDT	**Introduction/Overview** Vincenzo Bronte, MD – *Veneto Institute of Oncology*
1:45 p.m. PDT	**Reprogramming of Tumor-associated Immunosuppressive Myelopoiesis for the Benefit of Immunotherapy** Paulo C. Rodriguez, PhD – *Moffitt Cancer Center*
2:10 p.m. PDT	**Ferroptosis in Tumor Microenvironment** Dmitry I. Gabrilovich, MD, PhD – *AstraZeneca*
2:35 p.m. PDT	**Metabolic Switch of Immunosuppressive Myelopoiesis in Cancer** Antonio Sica, PhD – *University of Eastern Piedmont, Italy*
3 p.m. PDT	**Targeting Macrophage Lipid Metabolism to Enhance Anti-tumor Responses** Jennifer L. Guerriero, PhD – *Brigham and Women's Hospital*
3:25 p.m. PDT	**Break**

	Session IV: Therapeutic Targeting of Myeloid Cells in Cancer
Time:	3:40–5:30 p.m. PDT
Location:	Upper Level – Ballroom 6CD San Diego Convention Center
Moderator:	Jennifer L. Guerriero, PhD – *Brigham and Women's Hospital*
3:40 p.m. PDT	**Introduction/Overview** Jennifer L. Guerriero, PhD – *Brigham and Women's Hospital*
3:45 p.m. PDT	**Dendritic Cells** Ira Mellman, PhD – *Genentech*
4:10 p.m. PDT	**Enhanced Targeting of Myeloid Derived Suppressor Cells in Melanoma with ATRA and Checkpoint Inhibitors** Martin McCarter, MD – *University of Colorado School of Medicine*
4:35 p.m. PDT	**Develop a Novel Class of Myeloid Checkpoint Inhibitors by Targeting LILRB Family of Myeloid Inhibitory Receptors** Charlene Liao, PhD – *Immune-Onc Therapeutics, Inc.*
5 p.m. PDT	**Learning from the Clinic to Improve Success of Myeloid Cell Targeting Therapies** Simon Barry, PhD – *AstraZeneca*
5:25 p.m. PDT	**Closing Remarks** Jennifer L. Guerriero, PhD – *Brigham and Women's Hospital*